B. Metzler Seel. Sohn & Co. Ag Halozyme Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 33,183 shares of HALO stock, worth $1.41 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
33,183
Previous 42,435
21.8%
Holding current value
$1.41 Million
Previous $2.22 Million
14.54%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
542Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$750 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$549 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$282 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$173 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$145 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $5.93B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...